Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
| ▸ | CHKA | P35790 | 6/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.61 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19671018 | 0.93 | CHKA (0.77) | LMNAMC4RCHKAPOLBALDH1A1 | |
| SCHEMBL18753866 | 0.88 | POLB (0.55) | LMNAMC4RCHKAPOLBALDH1A1 | |
| SCHEMBL17465327 | 0.88 | CHKA (0.87) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL8254073 | 0.85 | ALDH1A1 (0.74) | LMNAMC4RPOLBALDH1A1KDM4E | |
| SCHEMBL13061368 | 0.84 | LMNA (0.65) | LMNAMC4RCHKAALDH1A1CA2 | |
| SCHEMBL8244422 | 0.83 | SIGMAR1 (0.75) | LMNAMC4RPOLBALDH1A1KDM4E | |
| SCHEMBL2056138 | 0.83 | LMNA (0.69) | LMNAMC4RCHKAPOLBALDH1A1 | |
| SCHEMBL82686 | 0.83 | LMNA (0.71) | LMNAMC4RCHKAPOLBALDH1A1 | |
| SCHEMBL8244456 | 0.83 | HRH3 (0.74) | POLBALDH1A1NCF1KDM4EMEN1 | |
| SCHEMBL12504054 | 0.82 | ALDH1A1 (0.65) | LMNAMC4RPOLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230255240-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | MIDORI USA, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2022255399-A1 | G9A INHIBITOR | 国立研究開発法人理化学研究所 | 2022-12-08 | — | — | WO | disclosed |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | GILEAD SCIENCES, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20210121486-A1 | ANIMAL THERAPEUTIC AND FEED COMPOSITIONS AND METHODS OF USE | HERCULES CAPITAL, INC. | 2021-04-29 | — | — | US | disclosed |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, HIPK2 | LMNA 3736/4885MC4R 4397/4885CHKA 660/4885 |
| US-20230255240-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | FUT5, FUT6, OSTC | LMNA 3367/4885MC4R 607/4885CHKA 3195/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | LMNA 4817/4885MC4R 1157/4885CHKA 630/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | LMNA 4411/4885MC4R 1384/4885CHKA 2724/4885 |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | LMNA 3537/4885MC4R 3886/4885CHKA 295/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | LMNA 1907/4885MC4R 4061/4885CHKA 2211/4885 |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | LMNA 3736/4885MC4R 4397/4885CHKA 660/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | LMNA 4833/4885MC4R 1232/4885CHKA 1431/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | LMNA 1962/4885MC4R 795/4885CHKA 1289/4885 |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | LMNA 1719/4885MC4R 4659/4885CHKA 156/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | LMNA 3736/4885MC4R 4397/4885CHKA 660/4885 |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | LMNA 2850/4885MC4R 1051/4885CHKA 1861/4885 |
| US-20210121486-A1 | ANIMAL THERAPEUTIC AND FEED COMPOSITIONS AND METHODS OF USE | FUT6, FUT5, PIGS | LMNA 3454/4885MC4R 470/4885CHKA 3488/4885 |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | LMNA 1719/4885MC4R 4659/4885CHKA 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.